A durable response to relapsing Clostridium difficile colitis may require combined therapy with high-dose oral vancomycin and intravenous immune globulin

Infectious Diseases in Clinical Practice

Volumn 14, Issue 4, 2006, Pages 217-220

  Cone, Lawrence A ^a,b   Lopez, Carlos ^a   Tarleton, Harold L ^a   Jodoin, V Douglas ^a   Taylor, Murray ^a   Gade Andavolu, Radikha ^b   Dreisbach, Luke P ^a  

^a EISENHOWER MEDICAL CENTER   (United States)

^b Genetic Research Institute of the Desert   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN; IMMUNOGLOBULIN G ANTIBODY; PROBIOTIC AGENT; VANCOMYCIN;

ADULT; AGED; ANTIBODY PRODUCTION; ARTICLE; CAUSE OF DEATH; CLINICAL ARTICLE; CLOSTRIDIUM DIFFICILE; COLITIS; CONGESTIVE HEART FAILURE; DISEASE ASSOCIATION; DRUG MEGADOSE; DRUG RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; MALE; PNEUMONIA; RECURRENT DISEASE; SACCHAROMYCES BOULARDII; TREATMENT RESPONSE;

EID: 33746684942     PISSN: 10569103     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.idc.0000222619.48650.d2     Document Type: Article

References (22)

1. Kelly CP, Pothoulakis C, LaMont JT. Clostridium difficile colitis. N Engl J Med. 1994;330:259-262.
2. Warny M, Pepin J, Killgore G, et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet. 2005;366:1079-1084.
3. Geric B, Rupnik M, Gerding DN, et al. Distribution of Clostridium difficile variant toxinotypes and strains with binary toxin genes among clinical isolates in an American hospital. J Med Microbiol. 2004;53:887-894.
4. Pothoulakis C. Pathogenesis of Clostridium difficile-associated diarrhea. Eur J Gastroenterol Hepatol. 1996;8:1041-1047.
5. Kyne L, Warny M, Qamar A, et al. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N Engl J Med. 2000;342:390-397.
6. McFarland LV, Surawicz CM, Rubin M, et al. Recurrent Clostridium difficile disease: epidemiology and clinical characteristics. Infect Control Hosp Epidemiol. 1999;20:43-50.
7. Fekety R, McFarland LV, Surawicz CM, et al. Recurrent Clostridium difficile diarrhea: characteristics of and risk factors for patients enrolled in a prospective, randomized, double-blinded trial. Clin Infect Dis. 1997;24:324-333.
8. Do AN, Fridkin SK, Yechouron A, et al. Risk factors for early recurrent Clostridium difficile-associated diarrhea. Clin Infect Dis. 1998;26:954-959.
9. Nair S, Yadav D, Corpuz M, et al. Clostridium difficile colitis: factors influencing treatment failure and relapse - a prospective evaluation. Am J Gastroenterol. 1998;93:1873-1876.
10. Kyne L, Warny M, Qamar A, et al. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet. 2001;357:189-193.
11. Kyne L, Kelly CP. Recurrent Clostridium difficile diarrhoea. Gut. 2001;49:152-153.
12. Kyne L, Moran A, Keane C, et al. Hospital-acquired diarrhea in elderly patients: epidemiology and staff awareness. Age Ageing. 1998;27:339-343.
13. Olson MM, Shanholtzer CJ, Lee JT Jr, et al. Ten years of prospective Clostridium difficile-associated disease surveillance and treatment at the Minneapolis VA Medical Center. Infect Control Hosp Epidemiol. 1994;15:371-381.
14. Gryboski JD, Pellerano R, Young N, et al. Positive role of Clostridium difficile infection in diarrhea in infants and children. Am J Gastroenterol. 86:1991;685-689.
15. Leung DYM, Kelly CP, Boguniewicz M, et al. Treatment with intravenously administered gamma globulin of chronic relapsing colitis induced by Clostridium difficile toxin. J Pediatr. 1991;118:633-637.
16. Perlmutter DH, Leichtner AM, Godman A, et al. Chronic diarrhea associated with hypogammaglobulinemia and enteropathy in infants and children. Dig Dis Sci. 1985;30:1149-1155.
17. Hassett J, Myers S, McFarland L, et al. Recurrent Clostridium difficile infection in a patient with selective IgG1 deficiency treated with intravenous immune globulin and Saccharomyces boulardii. Clin Infect Dis. 1995;20 (suppl 2):S266-S268.
18. Kyne L, Sougioultzis S, McFarland LV, et al. Underlying disease severity as a major risk factor for nosocomial Clostridium difficile diarrhea. Infect Control Hosp Epidemiol. 2002;23:653-659.
19. Munoz P, Bouza E, Cuenca-Estrella M, et al. Saccharomyces cerevisiae fungemia: an emerging infectious disease. Clin Infect Dis. 2005;40:1625-1634.
20. Yip C, Loeb M, Salama S, et al. Quinolone use as a risk factor for nosocomial Clostridium difficile-associated diarrhea. Infect Control Hosp Epidemiol. 2001;22:572-575.
21. Gaynes R, Rimland D, Killium E, et al. Outbreak of Clostridium difficile infection in a long-term care facility: association with gatifloxacin use. Clin Infect Dis. 2004;38:640-645.
22. Giannasca PJ, Warny M. Active and passive immunization against Clostridium difficile diarrhea and colitis. Vaccine. 2004;22:848-856.